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Background: The use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. 
However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not 
been fully investigated. We compared the glucose-lowering efficacies of DPP 4 inhibitors and evaluate their effects on the blood 
levels of cyclosporine in renal transplant recipients with diabetes. 
Methods: Sixty-five renal allograft recipients who received treatment with DPP-4 inhibitors (vildagliptin, sitagliptin, or lina-
gliptin) following kidney transplant were enrolled. The glucose-lowering efficacies of the DPP-4 inhibitors were compared ac-
cording to the changes in the hemoglobin A1c (HbA1c) levels after 3 months of treatment. Changes in the trough levels of the cy-
closporine were also assessed 2 months after treatment with each DPP-4 inhibitor. 
Results: HbA1c significantly decreased in the linagliptin group in comparison with other DPP-4 inhibitors (vildagliptin 
–0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin –1.40±1.34; P=0.016). Cyclosporine trough levels were signifi-
cantly increased in the sitagliptin group compared with vildagliptin group (30.62±81.70 ng/mL vs. –24.22±53.54 ng/mL, 
P=0.036). Cyclosporine trough levels were minimally changed in patients with linagliptin.
Conclusion: Linagliptin demonstrates superior glucose-lowering efficacy and minimal effect on cyclosporine trough levels in 
comparison with other DPP-4 inhibitors in kidney transplant patients with diabetes. 
Keywords: Dipeptidyl-peptidase IV inhibitors; Sitagliptin phosphate; Vildagliptin; Linagliptin; Cyclosporine; Kidney transplan-
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INTRODUCTION
Kidney transplantation (KT) has become the treatment of choice 
for end-stage renal disease [1]. With modern advances in surgical 
techniques and immunosuppressant medications, life expectancy 
following KT has increased [1] and controlling chronic metabolic 
complications such as diabetes mellitus is considered an impor-
tant medical issue [2].
 Dipeptidyl peptidase-4 (DPP-4) inhibitors are new oral glu-
cose-lowering agents that prevent the inactivation of glucagon-
like peptide-1 and stimulate insulin secretion in a glucose-depen-
dent manner [3]. Because the efficacies of DPP-4 inhibitors for 
reducing blood glucose have been demonstrated by multiple clin-
ical trials [3,4], a rapid increase in their clinical use is anticipated 
[5]. Although different DPP-4 inhibitors showed similar glucose-
lowering efficacies [5], they demonstrated various metabolic and 
excretory properties. Some are metabolized by the cytochrome 
P450 3A system [6], and their intestinal absorption and renal ex-
cretion might be affected by P-glycoprotein, an efflux transporter 
involved in the absorption and/or elimination of the drug [7].
 Cyclosporine is a calcineurin inhibitor and immunosuppressive 
agent that is widely used in organ transplants and some autoim-
mune diseases [8,9]. However, they have a narrow therapeutic 
window, and levels below this window are associated with an in-
creased risk for rejection, whereas levels above the window are 
correlated with side effects such as nephrotoxicity, neurotoxicity, 
hepatotoxicity, and hypertension [10]. Furthermore, because cy-
closporine is mainly metabolized in the liver by the cytochrome 
P450 3A system, as well as P-glycoprotein substrates [11], vari-
ous compounds that induce or inhibit the cytochrome P450 3A 
system or P-glycoprotein may influence the trough concentra-
tions of cyclosporine [12,13].
 Although the concurrent use of DPP-4 inhibitors and immuno-
suppressants are expected to increase among organ transplant pa-
tients with diabetes mellitus, the glucose-lowering efficacy of 
various DPP-4 inhibitors and their effects on the concentrations 
of calcineurin inhibitors have not been fully investigated. 
 In our current study, we compare the glucose-lowering effica-
cies of three different DPP-4 inhibitors (vildagliptin, sitagliptin, 
and linagliptin) and evaluate their effects on the trough levels of 
cyclosporine in KT recipients with diabetes mellitus. 
METHODS 
Study subjects 
We conducted the retrospective, longitudinal, observational 
study on patients who underwent KT between 2000 and 2013 
at Yonsei University Health System (Seoul, Korea) or Asan 
Medical Center (Seoul, Korea). Among them, renal allograft 
recipients with diabetes who initiated treatment with DPP-4 in-
hibitor (vildagliptin, sitagliptin, and linagliptin) after transplan-
tation were enrolled in this study. All KT recipients in both 
hospital received triple maintenance therapy which was com-
posed of cyclosporine, mycophenolate mofetil or azathioprine, 
and corticosteroid. All study patients survived >12 months af-
ter transplant. 
Lifestyle factors and measurements
Height (m) and weight (kg) were measured while each patient 
was wearing light clothing without shoes. Body mass index 
(kg/m2) was calculated as weight in kilograms divided by the 
square of height in meters. Patients with diabetes were defined 
as those with a fasting plasma glucose (FPG) ≥7.0 mmol/L, 
hemoglobin A1c (HbA1c) ≥6.5%, and/or receiving antidiabet-
ic medications at 1 year after transplantation. 
 After overnight fasting, blood samples were drawn from the 
antecubital vein in the early morning. Fasting total cholesterol, 
high density lipoprotein cholesterol, low density lipoprotein 
cholesterol, and triglyceride levels were measured using the en-
zymatic colorimetric method (Toshiba Medical System Co., To-
kyo, Japan). FPG concentrations were measured using enzymat-
ic colorimetric hexokinase (Toshiba Medical System Co.) meth-
ods on the Hitachi 7600 system (Hitachi Co., Tokyo, Japan).
 HbA1c was measured using the immunoturbidimetric meth-
od on the Cobas Integra 800 System (Roche Diagnostics, Ba-
sel, Switzerland). Follow-up HbA1c values were measured af-
ter 3 months of treatment with the DPP-4 inhibitors. This sys-
tem is standardized by the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC); however, Nation-
al Glycohemoglobin Standardization Program (NGSP) ap-
proved this measuring system. This machine automatically 
converts mmol/mol (IFCC) into % (NGSP).
 Cyclosporine trough levels were measured by immunoassay 
methods using the Dimension EXL 200 Integrated Chemistry 
System (Asan Medical Center) or the Affinity Column Mediat-
ed Immunoassay method using the Dimension RXL Max (Yon-
sei University Health System). Venous samples were drawn 12 
hours after the last dose (i.e., immediately before the next dose) 
in order to measure the trough levels. Changes in the serum cy-
closporine trough levels after 2 months treatment were also as-
sessed. Creatinine was measured using the Jaffe method, and 
the estimated glomerular filtration rate was calculated using the 
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Modification of Diet in Renal Disease study equation [14].
Statistical analysis
Continuous variables with normal distributions are expressed 
as the mean±standard deviation. Categorical variables are ex-
pressed as percentages (%). The characteristics of the study 
population (according to the type of DPP-4 inhibitor) were 
compared using one-way analysis of variance for continuous 
variables, or the chi-square test for categorical variables. The 
post hoc analysis was performed using Scheffe’s method. Fol-
low up HbA1c values were measured after 3 months of treat-
ment with the DPP-4 inhibitor and compared with the baseline 
values using paired t tests. All statistical analyses were per-
formed using SPSS version 19.0 (IBM Co., Armonk, NY, 
USA). P values <0.05 were considered statistically significant. 
RESULTS 
Sixty-five patients who initiated treatment with DPP-4 inhibi-
tors (vildagliptin, sitagliptin, and linagliptin) after KT were an-
alyzed. Twenty-five of these patients underwent KT at Yonsei 
University Health System, 40 patients underwent KT at Asan 
Medical Center. The mean age at the initiation of DPP-4 inhibi-
tor was 52.05±9.76 years, and the mean duration of diabetes 
Table 1. Characteristics of Patients and the Effect of DPP-4 Inhibitors on HbA1c     
Variable Vildagliptin (n=17) Sitagliptin (n=28) Linagliptin (n=20) P value
Age at KT, yr 50.71±12.32 52.29±8.53 45.00±8.15 0.035
Age at treatment of DPP-4 inhibitors, yr 52.53±13.04 54.14±8.05 48.70±8.19 0.159
Time between KT and DPP-4 inhibitor initiation, yr 1.82±3.00 1.86±3.31 3.70±4.24 0.160
Sex, male:female 12:05 18:10 8:12 0.121
Body mass index, kg/m² 22.87±3.69 23.42±2.40 24.08±3.60 0.512
Duration of diabetes, yr 5.46±5.55 9.70±7.76 8.38±9.17 0.315
Baseline creatinine, mg/dL 1.32±0.29 1.12±0.30 1.16±0.39 0.125
Follow-up creatinine, mg/dL 1.41±0.95 1.22±0.82 1.25±0.42 0.265
Baseline eGFR, mL/min/1.73 m² 60.68±13.19 69.32±17.85 66.08±25.65 0.364
Follow-up eGFR, mL/min/1.73 m² 58.21±17.76 61.03±16.50 62.82±18.74 0.160
Fasting plasma glucose, mg/dL 134.88±45.01 139.00±51.92 142.90±63.40 0.904
Postprandial glucose, mg/dL 201.75±55.26 211.00±78.14 290.0±135.63 0.207
Baseline HbA1c, % 7.57±2.11 7.76±1.53 8.11±1.29 0.578
After treatment HbA1c, % 7.08±1.81 7.18±1.21 6.79±0.63 0.561
Difference of HbA1c (ΔHbA1c), %a –0.38±1.03 –0.53±0.95 –1.40±1.34 0.016
Total cholesterol, mg/dL 193.49±35.09 215.31±76.16 196.42±54.56 0.420
Triglyceride, mg/dL 165.82±90.73 164.96±103.88 170.50±66.56 0.981
HDL-C, mg/dL 46.06±11.55 57.35±18.78 56.75±15.91 0.068
LDL-C, mg/dL 114.12±22.89 126.55±57.10 115.48±47.92 0.635
Dose of DPP-4 inhibitor, %
Full doseb
Reduced dosec
  
67.7
32.3
  
95.3
4.7
  
100
-
<0.001
  
  
Antidiabetic medication, %
DPP-4 inhibitor only 
DPP-4 inhibitor+other OHA
DPP-4 inhibitor+insulin
  
9.2
87.7
3.1
  
7.8
90.6
1.6
  
27.6
69.0
3.4
0.067
  
  
  
Values are expressed as mean±SD.    
DPP-4, dipeptidyl peptidase-4; HbA1c, hemoglobin A1c; KT, kidney transplantation; eGFR, estimated glomerular filtration rate; HDL-C, high den-
sity lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; OHA, oral hypoglycemic agent.    
aPost hoc analysis using Scheffe’s method was used to compare ΔHbA1c (vildagliptin vs. sitagliptin, P=no sigficant difference; vildagliptin vs. lina-
gliptin, P=0.039; sitagliptin vs. linagliptin, P=0.036); bA full dose of vildagliptin was 50 mg twice daily and sitagliptin was 100 mg once daily; cA 
reduced dose of vildagliptin and sitagliptin was 50 mg once daily.    
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was 8.14±7.80 years. 
 Table 1 shows the clinical and biochemical characteristics of 
the patients according to the type of DPP-4 inhibitor adminis-
tered at baseline. Subjects in sitagliptin group were slightly old-
er at the KT than other DPP-4 inhibitor groups (P=0.049). Age 
at DPP-4 inhibitor initiation was not different among the groups. 
According to renal function, sitagliptin and vildagliptin doses 
were adjusted. Both agents were treated with 50 mg once daily 
in renal insufficient patients. All of the patients in linagliptin 
group received full dose DPP-4 inhibitor medication. Concur-
rent anti-diabetic medications were similar among the groups.
 The HbA1c values measured 3 months after treatment with 
DPP 4 inhibitors were significantly lower in comparison with 
baseline in all groups (Table 1). When we compared glucose 
lowering efficacy of DPP-4 inhibitors through the changes in 
HbA1c from baseline to 3 months of treatment, the levels of 
HbA1c decreased significantly in the linagliptin group com-
pared with other DPP-4 inhibitor groups (vildagliptin 
–0.38%±1.03%, sitagliptin –0.53%±0.95%, and linagliptin 
–1.40±1.34; P=0.016). Even after excluding the patients re-
ceiving insulin therapy, the level of HbA1c significantly de-
creased in the linagliptin group (data not shown).
 Although there were no differences in baseline cyclosporine 
doses and blood levels, cyclosporine trough levels were signifi-
cantly increased in the sitagliptin group (30.62±81.70 ng/mL) 
in comparison with the vildagliptin group (–24.22±53.54 ng/
mL, P=0.031) (Table 2, Fig. 1). Cyclosporine trough levels 
were minimally changed in patients with linagliptin (–8.50±
54.35 ng/mL). There was no difference of change in cyclospo-
rine dose among the three groups (P=0.411) (Table 2, Fig. 1).
DISCUSSION 
In this observational longitudinal study, we found that lina-
gliptin showed a better glucose-lowering efficacy in compari-
son with other DPP-4 inhibitors in renal allograft recipients 
with type 2 diabetes. Furthermore, after 2 months of treatment 
with DPP-4 inhibitors, patients in the sitagliptin group demon-
strated increased serum cyclosporine trough levels in compari-
son with the vildagliptin group. 
 Hyperglycemia is associated with adverse long-term out-
comes in renal allograft recipients with diabetes [15-17], and 
glycemic control is an important factor for preventing allograft 
loss [16] and reducing patient mortality [17]. Recent data dem-
onstrated that impaired insulin secretion, rather than increased 
insulin resistance, played an important role in the development 
of diabetes in KT recipients [18], which indicated that the anti-
Table 2. Changes in Administered Doses and Trough Levels of Cyclosporine after 2 Months’ Treatment of Dipeptidyl Peptidase-4 In-
hibitors 
Variable Vildagliptin Sitagliptin Linagliptin P value
Baseline cyclosporine dose, mg/day 172.06±91.81 175.89±102.40 136.25±66.13 0.291
Follow-up cyclosporine dose, mg/day 147.06±61.16 155.36±54.16 131.25±60.63 0.369
Change in cyclosporine dose, mg/day –25.00±40.50 –20.54±65.99 –5.00±15.39 0.411
Baseline cyclosporine trough level, ng/mL 143.78±76.90 136.33±60.58 114.98±60.96 0.368
Follow-up cyclosporine trough, ng/mL 119.56±58.44 159.14±90.41 106.19±69.57 0.064
Change in cyclosporine trough level, ng/mL –24.22±53.54a 30.62±81.70b –8.50±54.35a,b 0.023
Values are expressed as mean±SD. Post hoc analysis of cyclosporine trough level using (Scheffe’s method-vildagliptin vs. sitagliptin, P=0.036; 
vildagliptin vs. linagliptin, P=0.780; sitagliptin vs. linagliptin, P=0.149).
a,bSame letters indicate no signiﬁcant differences between groups. 
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Fig. 1. Change in cyclosporine trough level. aVildagliptin vs. sita-
gliptin, P=0.036; vildagliptin vs. linagliptin, P=0.780; sitagliptin 
vs. linagliptin, P=0.149.
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diabetic agents that preserve or even improve pancreatic β-cell 
function may be beneficial for glycemic control in organ trans-
plant patients [18]. In previous studies, DPP-4 inhibitors dem-
onstrated protective effects toward pancreatic β-cell survival 
[19,20]. Furthermore, because several studies showed that 
DPP-4 inhibitors can be safely administered to patients with 
renal insufficiency at low risk for hypoglycemia [3,21], in-
creasing use of these medications in KT patients is expected.
 Various DPP-4 inhibitors showed similar efficacies in terms 
of lowering HbA1c [5], but their metabolism and excretion 
demonstrated widely variable properties [6]. Sitagliptin is pri-
marily eliminated in an unchanged form in the urine (79%), and 
a relatively small portion is metabolized by the hepatic cyto-
chrome P450 3A4 and 2C8 systems [22]. Vildagliptin is exten-
sively metabolized by multiple pathways that are not mediated 
by cytochrome P450 enzymes [23], and about two-thirds of the 
drug is excreted as a metabolite through the kidneys [24]. Vilda-
gliptin did not alter the pharmacokinetic of other drugs using P-
glycoprotein–mediated transport system [24]. Linagliptin is 
mainly eliminated in an unchanged form via the feces (84.7%), 
and renal excretion only accounts for 5.4% of elimination [25]. 
 In our study, linagliptin significantly reduced HbA1c levels 
in comparison with other DPP-4 inhibitors over the 3-month 
follow-up period. Furthermore, serum cyclosporine trough lev-
els increased significantly in the sitagliptin group, even though 
the administered doses of cyclosporine were decreased for 2 
months. Cyclosporine is extensively metabolized in the liver 
by the cytochrome P450 3A system [12], but the DPP-4 inhibi-
tors compared in our present study are not known as inhibitors 
or inducers of the cytochrome 450 system [6]. Thus, the differ-
ent effects of the DPP4-inhibitors on blood cyclosporine trough 
levels might not be explained by the drug interactions that are 
mediated by the cytochrome P450 system. Recently, clinically 
significant drug interactions mediated by P-glycoprotein have 
been described [11]. P-glycoprotein is an efflux transporter 
found in the enterocytes, hepatocytes, and renal tubular cells 
[11,26]. Regarding the drug interactions between sitagliptin 
and cyclosporine, Krishna et al. [27] reported that the sita-
gliptin AUC0-∞ (area under the concentration-time curves from 
time zero to infinity) increased in healthy male participants due 
to the inhibitory effects of cyclosporine on intestinal P-glyco-
protein. Considering that both sitagliptin and cyclosporine are 
substrates and inhibitors of P-glycoprotein [6,27,28], sitagliptin 
might inhibit intestinal P-glycoprotein in a competitive or non-
competitive manner and promote the absorption of cyclospo-
rine, which in turn increases serum cyclosporine trough levels. 
 Our study had limitations. First, we did not perform a formal 
pharmacokinetic study, which requires drawing multiple blood 
samples over the dosing interval. Thus, the trough levels of the 
calcineurin inhibitors might not have accurately reflected the 
AUC0-24 values. Second, we only checked the HbA1c and cy-
closporine levels at the baseline visit and at the first follow-up 
visit. Additional measures at multiple time points should make 
the conclusion more definite. Although dose of cyclosporine 
had changed with therapeutic dose monitoring within 2 months 
and dose of cyclosporine was not different among the DPP-4 
inhibitor groups, statistically insignificant change in cyclospo-
rine dose could affect the blood cyclosporine levels. However, 
our study, as a pilot study, has robust feature in that we first 
compared the glucose-lowering efficacy of DPP-4 inhibitors in 
renal allograft recipients and evaluated their effects on the 
blood concentrations of cyclosporine levels.
 In conclusion, we found in this pilot study that linagliptin 
demonstrates superior glucose-lowering efficacy and minimal 
effect on cyclosporine trough level in comparison with other 
DPP-4 inhibitors in kidney transplant patients with diabetes. In 
addition, patients who receive sitagliptin demonstrated signifi-
cantly increased cyclosporine trough levels through 2 months 
of treatment. However larger study and follow up study are 
warranted to get definite conclusion.  
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